Key Highlights

  • Shares were down 7.69% at USD 0.18 in pre-market trading on November 4, 2026.
  • The first Phase 2a patient was dosed on September 24, 2026, with topline data guided for the first quarter of 2027.
  • A USD 7.5 million Series C convertible preferred Placement was completed, with up to 4,512,400 common shares issuable on conversion.
  • Nu-3 showed only a slight rise in resistance in lab serial passage testing, against a 600 to 2,000 fold rise for ciprofloxacin.
  • The stock fell 19.31% on October 21, 2026, the day of its IDWeek data release.

What Moved Lakewood-Amedex Before the Open (down USD 0.0150, 7.69%)

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) was down 7.69%, or USD 0.0150, to USD 0.18 in pre-market trading on November 4, 2026, measured against the November 3 close. No company press release or regulatory filing dated November 2 to November 4, 2026 was identified as a catalyst for the move.

The decline fits a longer pattern. The shares closed at USD 1.50 before falling 20.00% to USD 1.20 on May 18, 2026, and the pre-market price is about 85% below that level (calculated). As a penny stock, it carries pronounced volatility, thin Liquidity and dilution risk, and the move may simply reflect continued pressure after a string of weak sessions.

Recent Company Updates

On October 21, 2026, the company presented laboratory data on Nu-3 at IDWeek 2026. It reported broad spectrum, rapid bactericidal activity against Gram positive, Gram negative and multidrug resistant bacteria, with eradication within minutes for the tested pathogens and activity against biofilm organisms. In serial passage testing, the minimum inhibitory concentration rose only slightly for S. aureus and E. coli.

The shares fell 19.31% that day despite the data, which were laboratory findings rather than patient results. On October 7, 2026, the company also reported preclinical data for another Bisphosphocin compound, Nu-8, which reduced E. coli growth by up to 97% in infected rodents.

Business Background

Lakewood-Amedex is a clinical stage company developing Bisphosphocin antimicrobials, led by Nu-3, a topical gel for mildly infected diabetic foot ulcers. The company said about half of diabetic foot ulcers become infected and an estimated 15% to 25% of infected ulcers involve resistant organisms, mainly MRSA. It began trading on the Nasdaq Capital Market on April 23, 2026 through a direct listing.

In May 2026, it reported that the Nu-3 drug substance is stable for at least five years and the gel formulation for at least two years, with undetectable bioburden without added preservatives.

Balance Sheet and Risks

In a letter to shareholders dated September 21, 2026, the company said it had completed a USD 7.5 million private placement of Series C Convertible Preferred Stock. Of 937,500 Preferred Shares issued, 486,260 had converted into common stock, leaving 451,240 outstanding, which could convert into up to 4,512,400 common shares, subject to price based terms and a 4.99% ownership cap.

Shareholders were asked at the September 22, 2026 annual meeting to raise authorized common stock from 12.5 million to 100 million shares and to approve a reverse split of up to 1 for 20, which the company said would be used only if needed to maintain Nasdaq listing requirements. The outcome of the vote and the current cash balance were not identified. Heavy conversion of preferred stock into common stock at a low share price is a clear dilution risk.

What to Watch Next

Key items include the third quarter 2026 report, any Nasdaq notice on the minimum bid price, the result of the authorized share and reverse split proposals, and enrollment news from the Phase 2a trial. Topline data are guided for the first quarter of 2027. Pre-market moves on thin Volume can reverse quickly once the regular session opens.